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Abstract
Background:  There is evidence from animal studies that serotonin (5-HT) can influence the
antinociceptive effects of opioids at the spinal cord level. Therefore, there could be an influence of genetic
polymorphisms in the serotonin system on individual variability in response to opioid treatment of pain.
The serotonin transporter (5-HTT) is a key regulator of serotonin metabolism and availability and its gene
harbors several known polymorphisms that are known to affect 5-HTT expression (e.g. 5-HTTLPR,
rs25531). The aim of this study was to investigate if the triallelic 5-HTTLPR influences pain sensitivity or
the analgesic effect of opioids in humans. 43 healthy volunteers (12 men, 31 women, mean age 26 years)
underwent heat pain stimulations before and after intravenous injection of Remifentanil; a rapid and potent
opioid drug acting on μ-type receptors. Subjects rated their perceived pain on a visual analogue scale
(VAS). All participants were genotyped for the 5-HTTLPR and the rs25531 polymorphism. We recruited
by advertising, with no history of drug abuse, chronic pain or psychiatric disorders.
Results: At baseline, there was no difference in pain ratings for the different triallelic 5-HTTLPR genotype
groups. However, the opiod drug had a differential analgesic effect depending on the triallelic 5-HTTLPR
genotype. Remifentanil had a significantly better analgesic effect in individuals with a genotype coding for
low 5-HTT expression (SA/SA and SA/LG) as compared to those with high expression(LA/LA), p < 0.02. The
analgesic effect for the three different genotype groups was linear to degree of 5-HTT expression.
Conclusion: This is the first report showing an influence of the triallelic 5-HTTLPR on pain sensitivity or
the analgesic effect of opioids in humans. Previously the 5-HTTLPR s-allele has been associated with higher
risk of developing chronic pain conditions but in this study we show that the genotype coding for low 5-
HTT expression is associated with a better analgesic effect of an opioid. The s-allele has been associated
with downregulation of 5-HT1 receptors and we suggest that individuals with a desensitization of 5-HT1
receptors have an increased analgesic response to opioids during acute pain stimuli, but may still be at
increased risk of developing chronic pain conditions.
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Introduction
Modern pain research has highlighted the importance of
central nervous system mechanisms for the regulation of
acute and chronic pain. The large individual differences in
pain sensitivity, response to analgesic drugs and risk of
developing chronic pain is partially explained by genetic
factors with impact on the endogenous pain modulation
that takes place within the central nervous system [1,2].
The activity of the descending pain inhibitory pathways is
largely dependent on dopamine/noradrenalin as well as
endogenous opioids and previous studies have shown
that polymorphisms in genes coding for μ-opioid recep-
tors and the catecholamine-degrading enzyme catechol-
O-methyltransferase (COMT) influence pain responses
[3,4]. However, in addition to well known opioidergic
pain regulatory mechanism with a key role of the rostral
ventromedial medulla (RVM), there is a separate seroton-
ergic channel from RVM that controls pain transmission
in the dorsal horn of the spinal cord in a state-dependent
manner [5]. Furthermore, there is evidence from animal
studies that serotonin (5-HT) can influence the antinocic-
eptive effects of opioids at the spinal cord level [6,7]. This
means that there may be a potential influence of func-
tional genetic polymorphisms of the serotonergic system
on individual variability in response to opioid treatment
of pain.
The serotonin transporter (5-HTT) is a key regulator of
serotonin metabolism. Localized in pre-synaptic neuronal
membranes it transports serotonin from the synapses
back into the presynaptic neuron thus terminating its syn-
aptic actions [8]. The human 5-HTT is encoded by one sin-
gle gene, SLC6A4, which contains several known
polymorphisms in its promoter region that affect the tran-
scriptional efficacy of the 5-HTT gene e.g. 5-HTTLPR (5-
HTT linked polymorphic region) [9] and rs25531 [10].
The 5-HTTLPR consists of a 43-bp insertion/deletion
yielding a short allele (s) and a long allele (l). The s-allele
reduces the transcriptional efficiency of the 5-HTT gene
promoter, resulting in decreased 5-HTT expression and
availability [9]. The s-allele has been reported to affect the
cerebral response to emotional stimuli [10] and to be
associated with higher neuroticism [11]. In the clinical
context, the s-allele has been associated with anxiety dis-
orders [12], substance abuse [13] as well as chronic pain
syndromes such as fibromyalgia [14], irritable bowel syn-
drome [15] and tension type headaches [16]. A single-
nucleotide polymorphism (rs25531) located in close
proximity of the 5-HTTLPR leading to an A to G substitu-
tion has been shown to further modulate the effect of the
5-HTTLPR on transcriptional efficacy. The minor G-allele
is almost always in phase with the 5-HTTLPR long allele
and reduces the transcriptional efficacy to the level associ-
ated with the 5-HTTLPR s-allele. Both polymorphisms are
commonly studied jointly and referred to as triallelic 5-
HTTLPR differentiating between individuals with a high
(LA/LA), intermediate (LA/LG, SA/LG) or low (SA/SA, LG/SA)
transcriptional efficacy. Despite the fact that the SNP
rs25531 is separate from the LPR and thus technically we
genotype two separate polymorphisms in strong LD, we
have chosen to use the established term "triallelic 5-
HTTLPR" to indicate that we are performing the same
analysis as in previous publications using this term [17].
Drugs inhibiting the 5-HTT and the norepinephrine trans-
porter (NET) (i.e. serotonin and norepinephrine re-
uptake inhibitors (SNRIs)) have antidepressive and anxi-
olytic effects, but also have antinociceptive effects [18-22].
Furthermore, SNRIs and, to a more limited extent, also
selective serotonin re-uptake inhibitors (SSRIs) have anal-
gesic effects in patients with neuropathic pain [23] and
fibromyalgia [24,25] two conditions associated with
changes in the function of endogenous pain modulation
and reports of insufficient analgesic response to opioids
[26,27]. Given the efficacy of serotonergic drugs in the
treatment of pain, genetic polymorphisms in the seroton-
ergic system may contribute to individual variability in
antinociceptive effects after opoid administration.
To our knowledge, no previous study has addressed the
possible influence of the triallelic 5-HTTLPR on pain sen-
sitivity or the analgesic effect of opioids in humans. The
aim of this pilot study was to investigate if; 1) heat pain
sensitivity, and 2) the relative analgesic effect of a short
acting opioid, differed between healthy subjects depend-
ent on the triallelic 5-HTTLPR genotype.
Methods
Participants were 43 healthy subjects (12 men and 31
women, mean age 26 years, SD 5), recruited by advertis-
ing. To meet the inclusion criteria subjects had to be over
18 years old, right-handed, take no medications (female
subjects were allowed to take contraceptive pills), have no
history of drug abuse, chronic pain or psychiatric disor-
ders. The psychiatric history was assessed by subjects' self-
report and not by formal interview. Anxiety dimensions
were addressed by the SpielbergerTrait Anxiety Inventory
(STAI-T) [28]. Subjects were recruited from a variety of
institutions in order to represent all sorts of educational
and professional backgrounds. All subjects were Cauca-
sian. The study was conducted according to the principles
expressed in the Declaration of Helsinki. The study was
approved by the Institutional Review Board of Karolinska
Institutet (Reference number 2005/950-31/1) and all
patients provided written informed consent for the collec-
tion of samples and subsequent analysis.
Subjects went through an experiment where pain was
induced to the dorsum of the left hand using a 3 × 3 cm
heat probe (Medoc TSA, Medoc Israel). In total two blocks
of 30 seconds of tonic heat (48°Celsius) were adminis-
tered at two different positions on the subjects' hand withMolecular Pain 2009, 5:37 http://www.molecularpain.com/content/5/1/37
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a ten minute interval. The order of the two positions on
the hand were counter-balanced. After each block subjects
were asked to rate the pain on a visual analogue scale
(VAS) ranging from 0 mm (no pain) to 100 mm (worst
imaginable pain). An intravenous injection of a short
acting and potent opioid acting on μ-receptors i.e.,
Remifentanil (4-(Methoxycarbonyl)-4-[(1-oxopropyl)
phenylamino]-1 – piperidine propa-noic acid methyl
ester) was given 15 seconds before the second heat stimu-
lation block. The administration of the opioid was overt
and before the injection the subject was informed that this
would be a fast acting opioid drug. The subject was also
informed that the effect of the drug would last approxi-
mately for the duration of the stimulation and then disap-
pear. Remifentanil has a rapid onset of action and a very
short duration. The time for a 50% reduction in the effect
site concentration is about 3.65 min and the terminal
elimination half-life 10.2 min at a dose of 2 μg/kg. The
minimal effective dose of Remifentanil in healthy con-
trols in our laboratory setting was determined in a previ-
ous pilot study and amounted to 0.08 μg/kg body weight,
which was used in this study. During the experiment the
subject and experimentator were blinded as to the genetic
category of the subject.
Genotyping
Samples of 20 ml whole blood were taken venously and
stored at -80°C until DNA extraction, which was per-
formed robotized by the local Biobank (KI Biobank, Karo-
linska Institutet, Stockholm) using standard methods.
(Autopure LS system [Gentra Systems, Minneapolis,
MN]). DNA yield was measured with UV at 260 nm and
with the 260/280 ratio as a quality check. Genotyping for
5-HTTLPR was performed as described in detail earlier
[29]. For the triallelic 5-HTTLPR a different protocol was
used and PCR reactions were performed in a final volume
of 20 μl containing 50 ng of genomic template, 0.2 mM
each deoxynucleoside triphosphate (dNTP), 0.4 mM each
primer, 0.05 U/μl Quiagen HotStar®Polymerase, 1 M Q-
Solution and 1× Buffer. The primer (Thermo Scientific,
Ulm, Germany) sequences were Forward: 5'-GGCGTT-
GCCGCTCTGAATGC-3' and Reverse. 5'-GAGGGACT-
GAGCTGGACAACCAC-3'. Samples were amplified on a
Biorad Tetrade (BIORAD, Hercules, CA, USA) with an ini-
tial denaturation step for 10 min at 94°C followed by 32
cycles consisting of denaturation for 30 s at 95°C, anneal-
ing for 30 s at 57°C and elongation for 30 s at 72°C and
one final elongation step for 5 min at 72°C. This yields a
"short" 486 bp and a "long" 529 bp fragment. 8 μl of the
PCR product separated for 2 h at 180 V on a 2.5% agarose
gel containing GelRed® and visualized using UV light. 10
μl of the remaining PCR product were digested for 12 h at
37°C with 0.1 μl MSP1 (New England Biolabs, Ipswich,
MA, USA) and 1 μl buffer per sample. MSP1 recognizes
and cuts a 5'-C/CGG-3' sequence resulting in the follow-
ing fragments: 340 bp, 127 bp and 62 bp for the LA allele,
297 bp, 127 bp and 62 bp for the SA allele, 174, 166, 127
and 62 bp for the LG allele and 166, 131, 127 and 62 bp
for the SA allele. Fragments were run for 2 h at 180 V on
4% Agarose gels containing GelRed® and visualized via UV
light. All biallelic 5-HTTLPR Genotypes were thus deter-
mined using two different protocols that yielded identical
results.
Statistics
We wanted to investigate the influence of the three differ-
ent triallelic 5-HTTLPR genotypes coding for low,
medium or high 5-HTT expression on the relative analge-
sic effect of Remifentanil. Therefore, the analysis of pain
ratings at baseline was based on raw scores, but when
investigating the relative effect of Remifentanil the pain
ratings were normalized in order to control for inter-indi-
vidual differences. The normalized VAS ratings were calcu-
lated by dividing the individual VAS rating following
Remifentanil by the individual VAS rating at baseline. The
differences between the three different triallelic 5-HTTLPR
genotypes in VAS ratings of heat pain at baseline and in
normalized VAS ratings following Remifentanil were ana-
lyzed by Kruskal-Wallis Tests. When significant differ-
ences were found, the Mann-Whitney U test was used to
perform individual group comparisons. Intragroup differ-
ences in VAS ratings before and after administration of
Remifentanil were analyzed by Wilcoxon's signed rank
test. Sex differences in heat pain sensitivity at baseline and
in normalized VAS ratings following Remifentanil were
analyzed by Mann Whitney U-test. A p-value of < .05 was
considered statistically significant (two-tailed tests).
Results
Genotyping yielded the following distribution for trial-
lelic 5-HTTLPR: 12 individuals homozygous for the long
allele (all LA/LA), 13 heterozygotes on a rs25531 A-allele
background (SA/LA), four heterozygotes with an LG allele
(SA, LG) and 10 individuals homozygous for the short
allele, all of which on a A-allele background (SA/SA) (see
Table 1). When grouping individuals based on their puta-
tive transcriptional efficacy, we compared 12 individuals
with a genotype coding for a high 5-HTT expression (LA/
LA) with 17 individuals with intermediate expression (LA/
SA) and 14 low expressing individuals (SA/SA and SA/LG).
Genotype distributions for 5-HTTLPR did not differ signif-
icantly from those predicted by the Hardy-Weinberg equi-
librium (HWE), chi2 = 0.02, p = 0.89. The distribution of
the rs25531 polymorphism did not differ from HWE
either; exact test, p = 1.0. The number of male/female sub-
jects for each of the genotype groups is shown in table 1.
Participants in the triallelic 5-HTTLPR genotype groups
did not differ significantly from each other in their trait
anxiety as assessed by the Spielberger Trait Anxiety inven-
tory [28], F(2,36) = 2.28, p = 0.12.Molecular Pain 2009, 5:37 http://www.molecularpain.com/content/5/1/37
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At baseline, there were no statistically significant differ-
ences between the three triallelic 5-HTTLPR genotypes in
heat pain sensitivity (see Figure 1). In order to validate the
experimental manipulation, we confirmed that the dose
of Remifentanil used had an analgesic effect in our study
population, W = -2.92, p < 0.005.
For normalized VAS ratings, the triallelic 5-HTTLPR geno-
type had a significant main effect on the analgesic effect of
the opiod drug, chi2 = 6.28, df = 2, p < 0.05 (See figure 2).
Remifentanil had a significantly better analgesic effect in
subjects with a genotype coding for low 5-HTT expression
(SA/SA and LG/SA) compared to subjects with high expres-
sion (LA/LA), chi2 = 6.01, df = 1, p < 0.02. The hetero-
zygous subjects (LA/SA) had an intermediate response to
Remifentanil and did not differ significantly in analgesic
response from either low, chi2 = 2.73, df = 1, p < 0.10 or
high expressing individuals, chi2 = 0.91, df = 1, p < 0.35.
The analgesic effect for each of the three genotype groups
was further explored in three separate analyses. Only sub-
jects homozygous with a genotype coding for low 5-HTT
expression (SA/SA and LG/SA) had a significant analgesic
effect of Remifentanil compared to baseline (p < 0.001),
while no statistically significant analgesic effect of
Remifentanil was seen in the other two genotype groups.
Heat pain ratings at baseline were higher in female sub-
jects (average: 60 mm, range: 20 – 85 mm) compared to
Table 1: Distribution of the triallelic 5-HTTLPR genotypes for men and women in the present sample (n = 43).
High expressing
(LA/LA)
Intermediate expressing
(LA/SA)
Low expressing
(SA/SA and LG/SA)
Male 43 5
Female 81 4 9
Total 12 17 14
Average ratings of heat pain intensity (mm VAS) ± SEM dur- ing 30 seconds of tonic contact heat stimuli corresponding to  48°Celsius in 43 healthy individuals grouped according to the  triallelic 5-HTTLPR genotypes, putative high (n = 12) inter- mediate (n = 17) and low 5-HTT expression (n = 14) Figure 1
Average ratings of heat pain intensity (mm VAS) ± 
SEM during 30 seconds of tonic contact heat stimuli 
corresponding to 48°Celsius in 43 healthy individuals 
grouped according to the triallelic 5-HTTLPR geno-
types, putative high (n = 12) intermediate (n = 17) 
and low 5-HTT expression (n = 14). There were no sta-
tistically significant differences between the genotype groups 
in heat pain sensitivity at baseline.
Normalized heat pain ratings following administration of  Remifentanil (0.08 μg/kg body weight) intravenously (average  ± SEM) during 30 seconds of tonic contact heat stimuli cor- responding to 48°Celsius in 43 healthy individuals grouped  according to the triallelic 5-HTTLPR genotype, putative high  (n = 12) intermediate (n = 17) and low 5-HTT expression (n  = 14) Figure 2
Normalized heat pain ratings following administra-
tion of Remifentanil (0.08 μg/kg body weight) intrave-
nously (average ± SEM) during 30 seconds of tonic 
contact heat stimuli corresponding to 48°Celsius in 
43 healthy individuals grouped according to the trial-
lelic 5-HTTLPR genotype, putative high (n = 12) 
intermediate (n = 17) and low 5-HTT expression (n = 
14). VAS ratings were normalized by dividing the individual 
VAS heat pain rating following Remifentanil with the individ-
ual VAS rating at baseline. Remifentanil had a significantly bet-
ter analgesic effect in subjects with low 5-HTT expression 
(SA/SA and SA/LG) compared to subjects homozygous for the 
5-HTTLPR LA allele (p < 0.02). Subjects with low 5-HTT 
expression rated the heat stimuli as significantly less painful 
following Remifentanil compared to baseline (p < 0.001). No 
statistically significant analgesic effect of Remifentanil was 
seen in the other two genotype groups.Molecular Pain 2009, 5:37 http://www.molecularpain.com/content/5/1/37
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male subjects (average: 46 mm, range 24 – 70 mm), chi2
= 6.28, df = 1, p < 0.02, but there were no statistically sig-
nificant sex differences in the normalized VAS ratings fol-
lowing administration of Remifentanil (female average
0.92, range 0.56 – 1.33; male 0.86, range 0.38 – 1.26),
chi2 = 0.19, df = 1, p = 0.66.
Discussion
We found that the triallelic 5-HTTLPR is associated with
individual differences in analgesic response to an opioid
drug in healthy subjects. Individuals with a genotype cod-
ing for low 5-HTT expression (SA/SA or SA/LG) responded
with more pain relief to Remifentanil than individuals
with a genotype coding for high (LA/LA) 5-HTT expression.
Interestingly we did not observe any difference in pain
sensitivity between the genotype groups at baseline,
which is in accordance with studies showing no difference
in the response to heat pain stimuli in 5-HTTLPR knock-
out and wild type mice [30,31]. To our knowledge, this is
the first report of an influence of the 5-HTTLPR polymor-
phisms on pain sensitivity in humans.
Serotonin has complex actions on nociception, with both
pro- and antinociceptive effects and differential effects
depending on the receptor type that is activated [32]. For
example, 5-HTTLPR knock-out mice have increased extra-
cellular levels of serotonin but the overall tissue content is
reduced [33,34]. Furthermore, complex compensatory
mechanisms with upregulation of certain 5-HT receptors
(i.e., 5-HT3) and down-regulation and/or decreased func-
tion of others (i.e. 5-HT2a and 5-HT1a, b) has been
reported in 5-HTTLPR knock-out mice which most likely
explains the lack of differences in pain sensitivity at base-
line [31]. Our data indicate that this may also be true for
the 5-HTTLPR polymorphisms in humans, although the
sensitivity to other modalities than heat pain remain to be
investigated as well as sensitivity to longer durations of
pain stimuli. In accordance with previous studies we
found higher pain sensitivity in females compared to
male subjects at baseline [35,36]. However, the relative
analgesic effect of Remifentanil did not differ between
male and female subjects.
The low dose of Remifentanil used in our study had a sig-
nificant analgesic effect that was further qualified by the
triallelic 5-HTTLPR genotype. Subjects with a genotype
coding for low 5-HTT expression (SA/SA and SA/LG) rated
the heat stimuli as significantly less painful following
Remifentanil compared to individuals with high expres-
sion (LA/LA) and those with an intermediate expression
showed an intermediate response. These findings may
seem contra-intuitive since individuals with the 5-
HTTLPR s-allele are overrepresented in various chronic
pain conditions [1,8] but our results are in accordance
with previous reports from animal studies investigating
the mechanisms involved in pain processing and analge-
sia. There are many types of serotonin receptors but the 5-
HT1a receptor plays a significant role in mediating pain
regulatory effects. Down-regulation of the function of
serotonin auto-receptors 5-HT1a and b have been docu-
mented in 5-HTTLPR knock-out mice [34,37] and desen-
sitization of the 5-HT 1a and b receptors is believed to be
of importance for the effects of antidepressive drugs [38]
inhibiting 5-HT reuptake. Individuals carrying an s-allele
have a reduced 5-HTT activity and therefore a compensa-
tory decrease in 5-HT1 activity would be expected [39].
There is evidence from animal studies that 5-HT1a ago-
nists inhibit opioid release in the dorsal horn of the spinal
cord [7] and reduce the analgesic effects of morphine [40].
Therefore increased analgesic effect of opioids, as seen in
our study in individuals with a triallelic 5-HTTLPR geno-
type coding for low 5-HTT expression, would be the
expected result of a desensitization of 5-HT1a receptors.
However, whereas 5-HT1a agonists have a hyperalgesic
effect during acute pain stimulation, they are known to
have analgesic effects during tonic painful stimulation
[41] Accordingly, 5-HT1a agonists have been shown to
have analgesic effects in animal models of nociceptive
[40] as well as neuropathic [42,43] pain, and the analgesic
effect increases with the duration of pain [41]. This
means, hypothetically, that individuals with a desensitiza-
tion of 5-HT1 receptors would have an increased analgesic
response to morphine and endogenous opioids during
acute pain stimuli, but may still be at increased risk of
developing chronic pain conditions. Our suggestion is
supported by a brain imaging study from 2007 [44] show-
ing that subjects with high availability of 5-HT1a recep-
tors exhibit low pain intensity accompanied by a high
capacity for central suppression of pain during a tonic
pain provocation, i.e., experimental cold pressor pain.
Considering these results, it would be of interest for future
studies to investigate a possible impact of genetic varia-
tion in the gene coding for the 5-HT1a receptor (e.g.
5HT1A -109C/G) on opoid induced analgesia.
On the first glance, our results seem to contradict the
results of Park et al. [45] who observed in a sample of
Korean patients suffering from chonic tension-type head-
ache that patients with the biallelic 5-HTTLPR s/s geno-
type (N = 76) use significantly more analgetic drugs than
patients carrying at least one 5-HTTLPR l-allele (N = 22).
The results are interpreted as defective pain control in
patients with the s/s genotype. However our study may
offer an alternative explanation for their results. We pro-
pose that carriers of the 5-HTTLPR l-allele use less analge-
sic drugs simply because they may not profit from their
analgesic effect to the same amount as patients with the s/
s genotype do. Furthermore Park et al. argue for an "over-
use" of analgesics seen in patients with the s/s genotype
but as more than 70% of the sample had this genotypeMolecular Pain 2009, 5:37 http://www.molecularpain.com/content/5/1/37
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they probably show a normal consumption while carriers
of the l-allele show a reduced consumption.
Our study had several limitations. The sample size was
small and the results from this study should therefore be
considered preliminary until there is validation from
future studies. Larger samples are needed to specifically
address the impact of the variations of the serotonin trans-
porter gene on opioid analgesia in relation to gender and
mood. Furthermore, the design of our study did not per-
mit a clear distinction between the analgesic effects of
endogenous opioids (due to expectation) from the effect
of the exogenous opiod, since both form part of the same
opioidergic physiological network [46].
In conclusion, we found that healthy subjects with the tri-
allelic 5-HTTLPR genotype coding for low 5-HTT expres-
sion (SA/SA and SA/LG) had a better analgesic effect of a
short acting opioid drug compared to those homozygous
for the 5-HTTLPR LA allele. The baseline sensitivity to heat
pain was not affected by the triallelic 5-HTTLPR polymor-
phism. Results from this exploratory study show that the
analgesic effect of a short acting opioid is influenced by
the triallelic 5-HTTLPR polymorphism in healthy humans
and the potential clinical implications of this finding need
to be explored.
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